TY - JOUR
T1 - Molecular profiling improves classification and prognostication of nodal peripheral t-cell lymphomas
T2 - Results of a phase III diagnostic accuracy study
AU - Piccaluga, Pier Paolo
AU - Fuligni, Fabio
AU - De Leo, Antonio
AU - Bertuzzi, Clara
AU - Rossi, Maura
AU - Bacci, Francesco
AU - Sabattini, Elena
AU - Agostinelli, Claudio
AU - Gazzola, Anna
AU - Laginestra, Maria Antonella
AU - Mannu, Claudia
AU - Sapienza, Maria Rosaria
AU - Hartmann, Sylvia
AU - Hansmann, Martin L.
AU - Piva, Roberto
AU - Iqbal, Javeed
AU - Chan, John C.
AU - Weisenburger, Denis
AU - Vose, Julie M.
AU - Bellei, Monica
AU - Federico, Massimo
AU - Inghirami, Giorgio
AU - Zinzani, Pier Luigi
AU - Pileri, Stefano A.
N1 - Funding Information:
Supported by Centro Interdipartimentale per la Ricerca sul Cancro "G. Prodi," BolognAIL, Associazione Italiana per la Ricerca sul Cancro, Fondazione Cassa di Risparmio in Bologna, Fondazione della Banca del Monte e Ravenna, and Progetto Strategico di Ateneo.
Funding Information:
Supported by Centro Interdipartimen- tale per la Ricerca sul Cancro “G. Prodi,” BolognAIL, Associazione Italiana per la Ricerca sul Cancro, Fondazione Cassa di Risparmio in Bologna, Fondazi-one della Banca del Monte e Ravenna, and Progetto Strategico di Ateneo.
Publisher Copyright:
© 2013 by American Society of Clinical Oncology.
PY - 2013/8/20
Y1 - 2013/8/20
N2 - Purpose The differential diagnosis among the commonest peripheral T-cell lymphomas (PTCLs; ie, PTCL not otherwise specified [NOS], angioimmunoblastic T-cell lymphoma [AITL], and anaplastic large-cell lymphoma [ALCL]) is difficult, with the morphologic and phenotypic features largely overlapping. We performed a phase III diagnostic accuracy study to test the ability of gene expression profiles (GEPs; index test) to identify PTCL subtype. Methods We studied 244 PTCLs, including 158 PTCLs NOS, 63 AITLs, and 23 ALK-negative ALCLs. The GEP-based classification method was established on a support vector machine algorithm, and the reference standard was an expert pathologic diagnosis according to WHO classification. Results First, we identified molecular signatures (molecular classifier [MC]) discriminating either AITL and ALK-negative ALCL from PTCL NOS in a training set. Of note, the MC was developed in formalin-fixed paraffin-embedded (FFPE) samples and validated in both FFPE and frozen tissues. Second, we found that the overall accuracy of the MC was remarkable: 98% to 77% for AITL and 98% to 93% for ALK-negative ALCL in test and validation sets of patient cases, respectively. Furthermore, we found that the MC significantly improved the prognostic stratification of patients with PTCL. Particularly, it enhanced the distinction of ALK-negative ALCL from PTCL NOS, especially from some CD30< PTCL NOS with uncertain morphology. Finally, MC discriminated some T-follicular helper (Tfh) PTCL NOS from AITL, providing further evidence that a group of PTCLs NOS shares a Tfh derivation with but is distinct from AITL. Conclusion Our findings support the usage of an MC as additional tool in the diagnostic workup of nodal PTCL.
AB - Purpose The differential diagnosis among the commonest peripheral T-cell lymphomas (PTCLs; ie, PTCL not otherwise specified [NOS], angioimmunoblastic T-cell lymphoma [AITL], and anaplastic large-cell lymphoma [ALCL]) is difficult, with the morphologic and phenotypic features largely overlapping. We performed a phase III diagnostic accuracy study to test the ability of gene expression profiles (GEPs; index test) to identify PTCL subtype. Methods We studied 244 PTCLs, including 158 PTCLs NOS, 63 AITLs, and 23 ALK-negative ALCLs. The GEP-based classification method was established on a support vector machine algorithm, and the reference standard was an expert pathologic diagnosis according to WHO classification. Results First, we identified molecular signatures (molecular classifier [MC]) discriminating either AITL and ALK-negative ALCL from PTCL NOS in a training set. Of note, the MC was developed in formalin-fixed paraffin-embedded (FFPE) samples and validated in both FFPE and frozen tissues. Second, we found that the overall accuracy of the MC was remarkable: 98% to 77% for AITL and 98% to 93% for ALK-negative ALCL in test and validation sets of patient cases, respectively. Furthermore, we found that the MC significantly improved the prognostic stratification of patients with PTCL. Particularly, it enhanced the distinction of ALK-negative ALCL from PTCL NOS, especially from some CD30< PTCL NOS with uncertain morphology. Finally, MC discriminated some T-follicular helper (Tfh) PTCL NOS from AITL, providing further evidence that a group of PTCLs NOS shares a Tfh derivation with but is distinct from AITL. Conclusion Our findings support the usage of an MC as additional tool in the diagnostic workup of nodal PTCL.
UR - http://www.scopus.com/inward/record.url?scp=84887253698&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84887253698&partnerID=8YFLogxK
U2 - 10.1200/JCO.2012.42.5611
DO - 10.1200/JCO.2012.42.5611
M3 - Article
C2 - 23857971
AN - SCOPUS:84887253698
SN - 0732-183X
VL - 31
SP - 3019
EP - 3025
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
IS - 24
ER -